FDA

By GREGORY ZELLER // Some fairly thick alphabet soup will create a tasty economic-development stew for regional food manufacturers. The Manufacturing & Technology Resource Consortium is partnering with the Port Washington-based Long Island Food Council on a multifaceted effort to bring expert consulting services to food manufacturers in Nassau and Suffolk. The MTRC/LIFC partnership will be a resource for clients of the MTRC, which is located on the Stony Brook University campus and serves as…

By GREGORY ZELLER // Scythian Biosciences Corp. is going public. The New York City/Toronto-based biotech, led by Great Neck investment banker Jonathan Gilbert on its quest to develop the world’s first pharmaceutical treatment for concussions, will begin trading Aug. 8 on the TSX Venture Exchange, one of Canada’s major stock markets. Projected to open at $8 (Canadian) per share, Scythian Biosciences (ticker symbol “SCYB”) will float upwards of 2.5 million shares – about half of…

The Food and Drug Administration has rescheduled a critical public hearing on potential regulations for the burgeoning stem cell industry. “Request for Comments – Draft Guidances Relating to the Regulation of Human Cells, Tissues or Cellular or Tissue-Based Products” will now be held Sept.12 and 13 inside the Masur Auditorium on the National Institutes of Health’s Bethesda, Md. campus. Originally scheduled for April 13, the hearing was postponed due to what the FDA called “considerable…

The Food and Drug Administration has indefinitely postponed a public hearing on stem cell regulation due to what it called “considerable interest.” “Due to this interest, and to give stakeholders additional time to provide comments to the agency, FDA intends to extend the comment period for the draft guidance documents,” the administration said on its website. The April 13 hearing was shaping up as a public showdown between opponents and supporters of stem cell-based research…